The tuning of PI3Kdelta kinase is a crucial process in immune cell biology. Impaired PI3K signaling is involved in several primary immunodeficiencies and in hematologic malignancies. Treatments targeting the PI3K kinase or the PI3K-AKT-mTOR signaling have been proposed in various immune disorders, especially in the presence of nonproliferation.
The Research Topic will focus on biological regulation of the PI3K-AKT-mTOR in healthy and diseased immune functions. The collection will address clinical and pathological aspects of primary immunodeficiencies, like Activated PI3Kdelta kinase (APDS) and Autoimmune Lymphoproliferative Syndrome (ALPS), characterized by dysregulated PI3K signaling. The collection will also focus on the pathogenesis of autoimmunity and inflammation associated with PI3K dysregulation. Moreover, the role of PI3K in hematologic malignancies and viral infections, such as EBV, can also be discussed. Finally, therapeutic approaches targeting the PI3K-AKP-mTOR pathway will be considered, as well as laboratory and clinical investigation useful in the follow-up of the treated patients.
The tuning of PI3Kdelta kinase is a crucial process in immune cell biology. Impaired PI3K signaling is involved in several primary immunodeficiencies and in hematologic malignancies. Treatments targeting the PI3K kinase or the PI3K-AKT-mTOR signaling have been proposed in various immune disorders, especially in the presence of nonproliferation.
The Research Topic will focus on biological regulation of the PI3K-AKT-mTOR in healthy and diseased immune functions. The collection will address clinical and pathological aspects of primary immunodeficiencies, like Activated PI3Kdelta kinase (APDS) and Autoimmune Lymphoproliferative Syndrome (ALPS), characterized by dysregulated PI3K signaling. The collection will also focus on the pathogenesis of autoimmunity and inflammation associated with PI3K dysregulation. Moreover, the role of PI3K in hematologic malignancies and viral infections, such as EBV, can also be discussed. Finally, therapeutic approaches targeting the PI3K-AKP-mTOR pathway will be considered, as well as laboratory and clinical investigation useful in the follow-up of the treated patients.
